Home/Pipeline/GEN3014 (HexaBody-CD38)

GEN3014 (HexaBody-CD38)

Multiple Myeloma

Phase 3Active

Key Facts

Indication

Multiple Myeloma

Phase

Phase 3

Status

Active

Company

Genmab

About Genmab

Founded in 1999, Genmab's mission is to improve the lives of patients through innovative antibody therapeutics. The company has achieved remarkable success with its partnered assets, DARZALEX® and KESIMPTA®, which have become multi-billion dollar therapies, validating its scientific approach. Its strategy combines advancing a deep, wholly-owned clinical pipeline with high-value collaborations, funded by substantial royalty revenue. This hybrid model positions Genmab to sustainably capture value from both its platform innovation and direct drug development.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Multiple Myeloma Drugs

Drug	Company	Phase	Status
Tasquinimod	Active Biotech	Preclinical	Active (Academic Partnership)
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
Kyprolis® (carfilzomib)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
inobrodib (CCS1477)	CellCentric	Phase 1/2	Active
ISB 2001	Ichnos Glenmark Innovation	Phase 1b	Active
In Vivo Cell Therapy	GigaMune	Pre-clinical	Active
Hemady	Dexcel Pharma USA	Approved	Commercial
AV-353	AVEO Oncology	Pre-clinical	Active
Sequesta™	ID4Pharma	Pre-clinical	Active
Myeloma Consortium	Criterium	Unknown	Active
GPRC5D x CD3 TCE	Integral Molecular	Preclinical	Available for License
RORA-Tscm CAR-T	RORABio	Pre-clinical	Active